CIRB Studies
Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
Study Number | Lead Group | Study Title | CIRB | Study Status |
---|---|---|---|---|
9672 | ETCTN | A Phase 2 Study of Nivolumab and Ipilimumab in Advanced Leiomyosarcoma of the Uterus | Adult CIRB - Early Phase Emphasis | Completed |
9671 | ETCTN | Exceptional Responders Pilot study: Molecular profiling of tumors from cancer patients who are Exceptional responders | Adult CIRB - Early Phase Emphasis | Completed |
9653 | ETCTN | Phase II Trial of Gemcitabine-Eribulin (GE) in Cisplatin Ineligible Patients with Advanced or Unresectable Unrothelial Carcinoma of the Bladder | Adult CIRB - Early Phase Emphasis | Completed |
9608 | ETCTN | A Phase I Trial of ABT-263 (Navitoclax); a Bcl-2 inhibitor; and Sorafenib (Nexavar) in Patients with Relapsed or Refractory Solid Organ Tumors | Adult CIRB - Early Phase Emphasis | Available to Open |
9571 | ETCTN | A phase IB study of the combination of AZD6244 hydrogen sulfate (selumetinib) and cyclosporin A (CsA) in patients with advanced solid tumors with an expansion cohort in metastatic colorectal cancer | Adult CIRB - Early Phase Emphasis | Completed |
9466 | ETCTN | Phase I/II study of dabrafenib, trametinib, and navitoclax in BRAF mutant melanoma (Phase I and II) and other solid tumors (Phase I only) | Adult CIRB - Early Phase Emphasis | Available to Open |
9149 | ETCTN | Molecular Profiling-based Assignment of Cancer Therapy for Patients With Advanced Solid Tumors | Adult CIRB - Late Phase Emphasis | Available to Open |
8329 | ETCTN | A Phase I/II Trial of ABT-888, an Inhibitor of Poly(ADP-ribose) Polymerase (PARP), and Topotecan (TPT) in Patients with Solid Tumors (Phase I) and Relapsed Ovarian Cancer or Primary Peritoneal Cancer (Phase II) After Prior Platinum Containing First-Line Chemotherapy | Adult CIRB - Early Phase Emphasis | Available to Open |
10614 | ETCTN | A Phase 1/2 Study of Nivolumab and Ipilimumab in Combination with Sirolimus and Prednisone in Kidney Transplant Recipients with Selected Unresectable or Metastatic Cutaneous Cancers | Adult CIRB - Early Phase Emphasis | Available to Open |
10612 | ETCTN | A Randomized Phase 2 Study of Daratumumab-Selinexor-Velcade-Dexamethasone (Dara-SVD) for High-Risk Newly Diagnosed Multiple Myeloma | Adult CIRB - Early Phase Emphasis | Available to Open |